

Michael H. May PhD

President & CEO Centre for Commercialization of Regenerative Medicine

Michael May is President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.

Michael sits on a number of boards and advisory committees including: the Centre for the Commercialization of Antibodies and Biologics (CCAB); AgeX Corporation; the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP); the Entrepreneurship Leadership Council at the University of Toronto; the TO Health! Human & Science Steering Committee; the Cell and Gene Therapy Insights, Editorial Advisory Board; the Commercialization Committee of the International Society for Cell and Gene Therapy; and the Executive Committee, Alliance for Regenerative Medicine (ARM). He is the Chairman of ExCellThera Ltd.

Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.